Marksans Pharma Ltd (MARKSANS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 604869, "name": "Marksans Pharma", "stock_name": "Marksans Pharma", "full_name": "Marksans Pharma Ltd", "name_url": "stocks-analysis/marksans-pharma", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "188.40", "chg": 11.25, "chgp": "6.35%", "dir": 1, "prev_price": "177.15", "mcapval": "8,537.60 Cr", "mcap": "Small Cap", "scripcode": 524404, "symbol": "MARKSANS", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE750C01026", "curr_date": "Feb 09", "curr_time": "", "bse_nse_vol": "8.64 lacs", "exc_status": "Active", "traded_date": "Feb 09, 2026", "traded_date_str": "2026 02 09", "score": "", "scoreText": "", "Live": 1, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/marksans-pharma-604869-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Marksans Pharma Ltd Faces Bearish Momentum Amid Technical Downgrade", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-faces-bearish-momentum-amid-technical-downgrade-3827819", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MarksansPharmaL_technicaldot_3827819.png", "date": "2026-02-09 08:01:15", "description": "Marksans Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. This change, reflected in the company’s recent price movements and technical metrics, raises concerns for investors amid a challenging market backdrop." }, { "title": "Marksans Pharma Gains 8.38%: 5 Key Factors Driving the Week’s Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-gains-838-5-key-factors-driving-the-weeks-volatility-3826501", "imagepath": "", "date": "2026-02-07 16:10:22", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>2 Feb:</strong> Stock opens at Rs.164.35, modest gain amid Sensex decline</p>\n <p><strong>3 Feb:</strong> Intraday high of Rs.186.60 on 13.14% surge, strong gap up</p>\n <p><strong>4 Feb:</strong> Mixed technical signals amid 1.67% dip, valuation concerns emerge</p>\n <p><strong>5 Feb:</strong> Q3 FY26 results released; technical downgrade follows</p>\n <p><strong>6 Feb:</strong> Mild recovery with 1.56% gain, technical momentum shifts</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs..." }, { "title": "Marksans Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-3823598", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MarksansPharmaL_technicaldot_3823598.png", "date": "2026-02-06 08:01:37", "description": "Marksans Pharma Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators. Despite a recent upgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical parameters reveal a landscape of cautious optimism tempered by lingering downside risks." }, { "title": "Are Marksans Pharma Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-marksans-pharma-ltd-latest-results-good-or-bad-3822920", "imagepath": "", "date": "2026-02-05 19:27:52", "description": "Marksans Pharma Ltd's latest financial results for the quarter ended December 2025 highlight a notable recovery in operational performance following previous challenges. The company reported a record quarterly revenue of ₹754.43 crores, reflecting a quarter-on-quarter growth of 4.72% and a year-on-year increase of 10.64%. This marks a significant rebound from the previous quarter's performance, where revenue growth was higher at 16.20%.\n\nNet profit for the same quarter reached ₹113.20 crores, showing a sequential increase of 15.22% and an 8.26% rise compared to the same period last year. Additionally, the operating margin improved to 21.31%, up from 20.06% in the prior quarter, indicating enhanced operational efficiency despite rising employee costs.\n\nHowever, the company has faced challenges, as evidenced by a decline in the growth rate of both revenue and net profit compared to the previous quarter. The n..." }, { "title": "Marksans Pharma Q3 FY26: Strong Quarter Marred by Valuation Concerns and FII Exit", "link": "https://www.marketsmojo.com/news/result-analysis/marksans-pharma-q3-fy26-strong-quarter-marred-by-valuation-concerns-and-fii-exit-3822810", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MarksansPharma_quaterlyResult_3822810.png", "date": "2026-02-05 17:46:43", "description": "Marksans Pharma Ltd., a mid-sized pharmaceutical manufacturer with a market capitalisation of ₹8,010 crores, delivered its strongest quarterly performance in Q3 FY26 with consolidated net profit reaching ₹113.20 crores—up 15.22% quarter-on-quarter and 8.26% year-on-year. However, the stock has tumbled 33.51% over the past year, trading at ₹179.55 as foreign institutional investors staged a dramatic exit and valuation concerns mounted despite operational improvements." }, { "title": "Marksans Pharma Ltd Faces Bearish Momentum Amid Technical Downgrade", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-faces-bearish-momentum-amid-technical-downgrade-3821665", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MarksansPharmaL_technicaldot_3821665.png", "date": "2026-02-05 08:02:50", "description": "Marksans Pharma Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 07 Jul 2025. The stock’s recent price action and technical indicators suggest a bearish trend, raising concerns for investors amid a challenging market environment." }, { "title": "Marksans Pharma Ltd Sees Mixed Technical Signals Amid Price Momentum Shift", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-sees-mixed-technical-signals-amid-price-momentum-shift-3819670", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MarksansPharmaL_technicaldot_3819670.png", "date": "2026-02-04 08:03:28", "description": "Marksans Pharma Ltd has experienced a notable shift in price momentum, reflected in a 10.28% surge in its share price to ₹181.25 on 4 Feb 2026. Despite this strong daily gain, technical indicators present a nuanced picture, with a blend of mildly bullish and bearish signals across weekly and monthly timeframes, prompting a reassessment of the stock’s near-term outlook." }, { "title": "Marksans Pharma Ltd Valuation Shifts Signal Price Attractiveness Concerns", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-valuation-shifts-signal-price-attractiveness-concerns-3819543", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MarksansPharmaL_valuationdot_3819543.png", "date": "2026-02-04 08:01:31", "description": "Marksans Pharma Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change, coupled with a recent upgrade in its Mojo Grade to Sell from Hold, highlights increasing price pressure despite mixed operational metrics and a challenging market backdrop." }, { "title": "Marksans Pharma Ltd Opens with Strong Gap Up Reflecting Positive Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-opens-with-strong-gap-up-reflecting-positive-market-sentiment-3817924", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MarksansPharmaL_gapup_3817924.png", "date": "2026-02-03 09:56:09", "description": "Marksans Pharma Ltd witnessed a significant gap up at the opening bell on 3 February 2026, surging 9.46% higher than its previous close. This robust start underscores a positive market sentiment towards the pharmaceutical company amid a broader sectoral uptick." } ], "total": 324, "sid": "604869", "stock_news_url": "https://www.marketsmojo.com/news/marksans-pharma-604869" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "06-Feb-2026", "details": "Newspaper Publication of Un-Audited Financial Results for the Quarter and Nine months ended 31 December 2025", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome", "datetime": "06-Feb-2026", "details": "Audio Recording of investor(s) / analyst(s) meet Conference Call on Q3 & 9M FY26 Financial Results", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation", "datetime": "05-Feb-2026", "details": "Marksans Investors Presentation Q3 and 9M FY 26", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Marksans Pharma Ltd has declared <strong>80%</strong> dividend, ex-date: 01 Aug 25", "dt": "2025-08-01", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Marksans Pharma Ltd has announced <strong>1:10</strong> stock split, ex-date: 11 Mar 08", "dt": "2008-03-11", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

2 Feb: Stock opens at Rs.164.35, modest gain amid Sensex decline

3 Feb: Intraday high of Rs.186.60 on 13.14% surge, strong gap up

4 Feb: Mixed technical signals amid 1.67% dip, valuation concerns emerge

5 Feb: Q3 FY26 results released; technical downgrade follows

6 Feb: Mild recovery with 1.56% gain, technical momentum shifts

Week Open

Rs...

Read full news article

Marksans Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-06 08:01:37

Marksans Pharma Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators. Despite a recent upgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical parameters reveal a landscape of cautious optimism tempered by lingering downside risks.

Read full news article

Are Marksans Pharma Ltd latest results good or bad?

2026-02-05 19:27:52

Marksans Pharma Ltd's latest financial results for the quarter ended December 2025 highlight a notable recovery in operational performance following previous challenges. The company reported a record quarterly revenue of ₹754.43 crores, reflecting a quarter-on-quarter growth of 4.72% and a year-on-year increase of 10.64%. This marks a significant rebound from the previous quarter's performance, where revenue growth was higher at 16.20%. Net profit for the same quarter reached ₹113.20 crores, showing a sequential increase of 15.22% and an 8.26% rise compared to the same period last year. Additionally, the operating margin improved to 21.31%, up from 20.06% in the prior quarter, indicating enhanced operational efficiency despite rising employee costs. However, the company has faced challenges, as evidenced by a decline in the growth rate of both revenue and net profit compared to the previous quarter. The n...

Read full news article

Marksans Pharma Q3 FY26: Strong Quarter Marred by Valuation Concerns and FII Exit

2026-02-05 17:46:43

Marksans Pharma Ltd., a mid-sized pharmaceutical manufacturer with a market capitalisation of ₹8,010 crores, delivered its strongest quarterly performance in Q3 FY26 with consolidated net profit reaching ₹113.20 crores—up 15.22% quarter-on-quarter and 8.26% year-on-year. However, the stock has tumbled 33.51% over the past year, trading at ₹179.55 as foreign institutional investors staged a dramatic exit and valuation concerns mounted despite operational improvements.

Read full news article

Marksans Pharma Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-02-05 08:02:50

Marksans Pharma Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 07 Jul 2025. The stock’s recent price action and technical indicators suggest a bearish trend, raising concerns for investors amid a challenging market environment.

Read full news article

Marksans Pharma Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

2026-02-04 08:03:28

Marksans Pharma Ltd has experienced a notable shift in price momentum, reflected in a 10.28% surge in its share price to ₹181.25 on 4 Feb 2026. Despite this strong daily gain, technical indicators present a nuanced picture, with a blend of mildly bullish and bearish signals across weekly and monthly timeframes, prompting a reassessment of the stock’s near-term outlook.

Read full news article

Marksans Pharma Ltd Valuation Shifts Signal Price Attractiveness Concerns

2026-02-04 08:01:31

Marksans Pharma Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change, coupled with a recent upgrade in its Mojo Grade to Sell from Hold, highlights increasing price pressure despite mixed operational metrics and a challenging market backdrop.

Read full news article

Marksans Pharma Ltd Opens with Strong Gap Up Reflecting Positive Market Sentiment

2026-02-03 09:56:09

Marksans Pharma Ltd witnessed a significant gap up at the opening bell on 3 February 2026, surging 9.46% higher than its previous close. This robust start underscores a positive market sentiment towards the pharmaceutical company amid a broader sectoral uptick.

Read full news article